The enormous profits of the pharmaceutical industry are dependent on government protected monopolies
Patent protected drugs only consist of 10% of the prescription drug market, but
constitute over 72% of drug spending.
When a drug loses its patent, its earning power is reduced by 80%-90%
Patent expirations between 2009 and 2014were estimated to have cost pharmaceutical corporations $120 billion in sales.
Expected patent expirations over the next 5 years are estimated to put at risk $215 billion in revenue.
Drug companies use ever-greening to maintain and prolong their monopolies
Ever-greening: Drug companies obtain new patents for existing drugs through minor
modifications of the original molecule. Between 1989 and 2000, 65% of Food and
Drug Administration approved applications for drugs contained already approved ingredients.
Many pharmaceutical companies turn to the medical devices that
administer the drug to uphold and prolong their monopolies
Drug companies use pay-to-delay to maintain and prolong their monopolies
Pay-to-delay: Pharmaceutical companies pay off generic manufacturers to delay the
release of generic versions of their drugs